Literature DB >> 16148590

High failure rate associated with 180 degrees selective laser trabeculoplasty.

Julia Song1, Paul P Lee, David L Epstein, Sandra S Stinnett, Leon W Herndon, Sanjay G Asrani, R Rand Allingham, Pratap Challa.   

Abstract

PURPOSE: To determine the efficacy of selective laser trabeculoplasty (SLT) in a tertiary care referral center. PATIENTS AND METHODS: In this retrospective study of selective laser trabeculoplasty performed by five physicians, 94 eyes from 94 patients were included. A majority (83/92, 90%) underwent 180 degrees selective laser trabeculoplasty. Selective laser trabeculoplasty failure was defined in two ways: (1) IOP decrease <3 mm Hg (definition one), or (2) IOP decrease <20% (definition two), on two successive visits > or =4 weeks after SLT.
RESULTS: Overall failure rates were 68% (64/94) and 75% (70/94) (by definitions one and two, respectively). By survival/life-table analysis, mean time to failure was 6 months and 5.5 months, by definitions one and two, respectively. By the end of the study (14.5 months), the failure rates were 86% and 92% by definitions one and two, respectively. By each definition, in both univariable and multivariable analysis, only lower baseline IOP was a significant predictor of failure.
CONCLUSIONS: Selective laser trabeculoplasty had an overall low success rate in our tertiary clinic population, with overall failure rates of 68% to 74% in those who underwent 180 degrees selective laser trabeculoplasty.

Entities:  

Mesh:

Year:  2005        PMID: 16148590     DOI: 10.1097/01.ijg.0000176939.43681.c2

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  33 in total

1.  Selective laser trabeculoplasty: predictive value of early intraocular pressure measurements for success at 3 months.

Authors:  P B Johnson; L J Katz; D J Rhee
Journal:  Br J Ophthalmol       Date:  2006-02-07       Impact factor: 4.638

2.  Efficacy and safety of selective laser trabeculoplasty as a primary procedure for controlling intraocular pressure in primary open angle glaucoma and ocular hypertensive patients.

Authors:  Mohamed A-M S Mahdy
Journal:  Sultan Qaboos Univ Med J       Date:  2008-03

3.  Selective laser trabeculoplasty.

Authors:  Jing-Ming Shi; Song-Bai Jia
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

4.  Clinical results of selective laser trabeculoplasty in silicone oil-induced secondary glaucoma.

Authors:  Miaomiao Zhang; Bin Li; Jianrong Wang; Wei Liu; Yan Sun; Xinyi Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-27       Impact factor: 3.117

5.  The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment.

Authors:  Marcelo Ayala; Enping Chen
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-16       Impact factor: 2.671

6.  [Effectiveness of selective laser trabeculoplasty in patients with insufficient control of intraocular pressure despite maximum tolerated medical therapy].

Authors:  C Hirn; S A Zweifel; M Töteberg-Harms; J Funk
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

7.  In vivo femtosecond laser subsurface scleral treatment in rabbit eyes.

Authors:  Dongyul Chai; Gautam Chaudhary; Eric Mikula; Hui Sun; Ron Kurtz; Tibor Juhasz
Journal:  Lasers Surg Med       Date:  2010-09       Impact factor: 4.025

8.  From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy.

Authors:  Jorge A Alvarado; Rumiko Iguchi; Richard Juster; Julie A Chen; Amde Selassie Shifera
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

9.  SELECTIVE LASER TRABECULOPLASTY--SHORT TERM EFFICACY AND SAFETY PROFILE IN OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION TREATMENT.

Authors:  Dorin Chiselita; Alina Cantemir; Anca Delia Pantalon
Journal:  Rom J Ophthalmol       Date:  2015 Jul-Sep

10.  West Indies Glaucoma Laser Study (WIGLS)-2: Predictors of Selective Laser Trabeculoplasty Efficacy in Afro-Caribbeans With Glaucoma.

Authors:  Tony Realini; Hazel Shillingford-Ricketts; Darra Burt; Goundappa K Balasubramani
Journal:  J Glaucoma       Date:  2018-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.